What changed?
Follow material changes recorded in BACToBasics: new curated research sources, trial readouts, phase advancements, regulatory submissions, approvals, and development-status changes. Every public timeline is generated from the same update records that power the Follow Updates inbox.
Compound timelines
23
Research records represented
30
Development entries represented
26
Latest recorded activity
A research-source addition is not the same thing as a regulatory or clinical-development change. The labels below keep those event types separate.
AOD-9604 · Phase 2 (historical) · Historical clinical development
AOD-9604 advanced into human obesity development through Phase 2-era studies, but the obesity program did not establish the efficacy needed to become an approved treatment and did not progress to approval.
BPC-157 · Exploratory human evidence · No established development program
BPC-157 has very limited reported human exposure, but there is no established modern clinical-development program demonstrating progression through conventional Phase 1, 2, and 3 milestones.
DSIP · Early human studies (historical) · Historical clinical development
DSIP was tested in small controlled human sleep studies decades ago, but the work predates a modern late-stage drug-development program and did not produce an approved therapy.
Epitalon · Preclinical / no established modern program · No established development program
Modern evidence for epitalon is dominated by laboratory, cell, and mechanistic work rather than a validated contemporary clinical-development pathway leading toward regulatory approval.
GHK-Cu · Early human evidence — topical route · No established development program
GHK-Cu has small human studies in topical/cosmetic contexts, but that route-limited evidence does not establish an injectable clinical-development program.
HCG · Approved · Approved
HCG is an established prescription glycoprotein hormone with FDA-licensed products and indication-specific medical use in reproductive endocrinology and selected hypogonadism-related settings.
IGF-1 LR3 · Preclinical / no established human program · No established development program
IGF-1 LR3 is discussed widely in research and performance communities, but a peer-reviewed clinical-development program for the exact analogue has not been established.
MOTS-C · Preclinical / human biology evidence · No established development program
MOTS-C has substantial interest as an endogenous mitochondrial-derived peptide, but human biology measurements are not the same as a validated therapeutic development program using administered MOTS-C.
MT2 / Melanotan II · Phase 1 (historical) · Historical clinical development
Melanotan II was studied in a pilot Phase 1 human program and later small controlled sexual-function studies, but it did not become an FDA-approved tanning or sexual-function medication.
PEG-MGF · Preclinical / no established human program · No established development program
PEG-MGF does not have an established peer-reviewed human clinical-development program. Findings involving native MGF or IGF-1 biology should not be transferred automatically to PEG-MGF.
Browse by compound
Timelines are indexable only after enough tracked material exists to make the page useful. Adding a qualifying research or development record automatically updates the appropriate timeline.
Historical Phase 2 obesity-development program; no approved product followed.
View timeline →
Limited exploratory human evidence; no validated late-stage therapeutic program identified.
View timeline →
Small double-blind insomnia studies reported weak or inconsistent clinical effects.
View timeline →
No established modern Phase 1–3 therapeutic program identified.
View timeline →
Small randomized topical study after CO2 laser resurfacing.
View timeline →
Longstanding FDA-licensed prescription products including Pregnyl.
View timeline →
No established direct human therapeutic development milestone identified.
View timeline →
Human biology is documented; no established approved or late-stage therapeutic program identified.
View timeline →
Pilot Phase 1 human study demonstrated tanning activity and dose-limiting adverse effects.
View timeline →
No established direct human therapeutic development milestone identified.
View timeline →
No established direct human therapeutic development milestone for TB-500 itself.
View timeline →
FDA-approved clinical use after Phase 3 development.
View timeline →
PERFORMA Phase 3 MASH trial initiated
View timeline →
TRIUMPH-1 delivered positive pivotal Phase 3 results
View timeline →
AMAZE Phase 3 obesity program initiated
View timeline →
REDEFINE 4 head-to-head results reported
View timeline →
Growth Hormone Secretagogues and Related Peptides: Evidence Review
View timeline →
Bulk Drug Substances That May Present Significant Safety Risks — Ipamorelin
View timeline →
MARITIME-1 and MARITIME-2 Phase 3 enrollment completed
View timeline →
Wegovy received accelerated FDA approval for MASH
View timeline →
China NMPA approved mazdutide for chronic weight management
View timeline →
FDA approved Zepbound for obesity-associated obstructive sleep apnea
View timeline →
MASH Phase 3 program initiated and FDA Breakthrough Therapy designation announced
View timeline →
A curated source was added to the Research Library. This does not by itself mean a compound changed development stage or regulatory status.
A dated milestone such as a trial readout, phase advancement, regulatory submission, approval, or material program-status change.
The current verified development state for a compound when a separate dated history event is not yet represented in the timeline.
BACToBasics provides educational research organization only. Update pages are not medical advice, treatment guidance, dosing advice, investment advice, or a prediction that an investigational compound will be approved.